.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
AstraZeneca
Deloitte
US Department of Justice
Moodys
Colorcon
McKinsey
Argus Health
Harvard Business School

Generated: September 25, 2017

DrugPatentWatch Database Preview

Somatropin recombinant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for somatropin recombinant and what is the scope of somatropin recombinant patent protection?

Somatropin recombinant
is the generic ingredient in twenty branded drugs marketed by Emd Serono, Lg Chem Ltd, Novo Nordisk Inc, Genentech, Sandoz, Emergent, Lilly, Ferring, and Pharmacia And Upjohn, and is included in fourteen NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Somatropin recombinant has one hundred and ninety-six patent family members in twenty-eight countries.

There are four drug master file entries for somatropin recombinant. Eight suppliers are listed for this compound.

Summary for Generic Name: somatropin recombinant

Tradenames:20
Patents:16
Applicants:9
NDAs:14
Drug Master File Entries: see list4
Suppliers / Packagers: see list8
Clinical Trials: see list1,570
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:somatropin recombinant at DailyMed

Pharmacology for Ingredient: somatropin recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
NORDITROPIN FLEXPRO
somatropin recombinant
INJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-006Oct 1, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-009Jan 27, 1998RXYesNo► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-004Oct 1, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Lilly
HUMATROPE
somatropin recombinant
INJECTABLE;INJECTION019640-007Feb 4, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Novo Nordisk Inc
NORDITROPIN
somatropin recombinant
INJECTABLE;INJECTION021148-001Jun 20, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Novo Nordisk Inc
NORDITROPIN FLEXPRO
somatropin recombinant
INJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-001Jan 27, 1998RXYesNo► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
NORDITROPIN FLEXPRO
somatropin recombinant
INJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-006Oct 1, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: somatropin recombinant

Non-Orange Book Patents for Generic Ingredient: somatropin recombinant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,582,404 Dose setting limiter► Subscribe
8,357,120Injection device with torsion spring and rotatable display► Subscribe
8,096,978Automatic injection device with a top release mechanism► Subscribe
7,686,786Dial-down mechanism for wind-up pen► Subscribe
9,616,180Automatic injection device with a top release mechanism► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: somatropin recombinant

Country Document Number Estimated Expiration
Portugal1034007► Subscribe
South Korea20000010630► Subscribe
Israel148609► Subscribe
China1509193► Subscribe
Russian Federation2388498► Subscribe
World Intellectual Property Organization (WIPO)9739768► Subscribe
Brazil0014030► Subscribe
Russian Federation2007127537► Subscribe
China101107032► Subscribe
Israel126463► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Merck
QuintilesIMS
Julphar
Cantor Fitzgerald
Covington
UBS
McKesson
US Department of Justice
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot